相关临床试验
93
9 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1986
进行中（未招募）
5
5.4%
已完成
56
60.2%
尚未招募
4
4.3%
招募中
10
10.8%
终止
6
6.5%
Unknown
6
6.5%
撤回
6
6.5%
暂无批准数据
- A clinical trial led by the Kirby Institute at UNSW Sydney demonstrated that point-of-care testing for hepatitis B DNA using fingerstick blood samples is as effective as traditional laboratory testing. - The fingerstick point-of-care test provides results within 60 minutes and can be performed by a broader range of healthcare workers in small health clinics. - This breakthrough could significantly expand access to hepatitis B testing and treatment in resource-limited settings and remote areas where current testing access is poor. - The findings support recent WHO guidelines recommending the use of hepatitis B point-of-care DNA fingerstick tests globally to help meet elimination targets by 2030.
- CEPI is providing $1 million to the African Vaccine Regulatory Forum (AVAREF) to enhance multi-country clinical trial application reviews, aiming to reduce approval times from 6-18 months to 10-15 days during health emergencies. - The Coalition has also committed up to $1.9 million to support FEEVA, a new framework that will develop standardized tools for evaluating early vaccine efficacy data to enable faster regulatory approvals. - Both initiatives directly support CEPI's ambitious 100 Days Mission to develop new vaccines in response to novel outbreaks within 100 days. - These projects address critical bottlenecks in vaccine development by streamlining regulatory processes in Africa and creating new evidence evaluation frameworks for global use.
